Welcome!

News Feed Item

PharmaPoint: Hemophilia A and B - China Drug Forecast and Market Analysis to 2022

NEW YORK, Jan. 16, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

PharmaPoint: Hemophilia A and B - China Drug Forecast and Market Analysis to 2022
http://www.reportlinker.com/p01957666/PharmaPoint-Hemophilia-A-and-B---China-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

PharmaPoint: Hemophilia A and B - China Drug Forecast and Market Analysis to 2022

Summary

The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant FVIII and FIX replacement factors, and patients with severe forms of the disease receive frequent prophylactic infusions beginning from the first one or two years of life and often continuing through adulthood. However, the burden on patients and their families to maintain the prophylactic treatment schedule is high, and there is a significant unmet need for new therapies that can reduce the number of weekly prophylactic infusions and alleviate some of this treatment burden.

Treatment options in China are extremely limited compared with the 7MM. Although some recombinant replacement therapies for hemophilia A and B, such as Recombinate, Xyntha, Kogenate, Advate and BeneFIX, are approved for marketing in China, they are not covered by national or provisional insurance programs and access to these drugs is extremely limited.

Scope

- Overview of Hemophilia A and B including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in China including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in China from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting China Hemophilia A and B market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Hemophilia A and B
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in China
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
2.3 Upcoming Related Reports 12
3 Disease Overview 13
3.1 Etiology and Pathophysiology 13
3.1.1 Etiology 13
3.1.2 Pathophysiology 14
3.1.3 Prognosis and Quality of Life 16

3.2 Symptoms 17
3.2.1 Hemophilia A and B 17
3.2.2 Inhibitors 18
4 Disease Management 19
4.1 Treatment Overview 19
4.1.1 Hemophilia A and B Diagnosis 20
4.1.2 Hemophilia A and B Treatment 20
4.1.3 Inhibitors Diagnosis 22
4.1.4 Inhibitors Treatment 22
4.2 China 24
4.2.1 Clinical Practice 24
5 Competitive Assessment 26
5.1 Overview 26
5.2 Strategic Competitive Assessment 27
5.3 Product Profiles - Major Brands, Hemophilia A 31
5.3.1 Advate (octocog alfa; Antihemophilic Factor [Recombinant] Plasma/Albumin-Free) 31
5.3.2 Kogenate FS/Helixate FS (Antihemophilic Factor (Recombinant)) 35
5.3.3 Recombinate (octocog alfa; Antihemophilic Factor [Recombinant] Plasma/Albumin-Free) 38
5.4 Product Profiles - Hemophilia B 40
5.4.1 BeneFIX (nonacog alfa; coagulation factor IX [recombinant]) 40
5.4.2 Rixubis (BAX-326) 43
5.5 Product Profiles - Hemophilia A and B with Inhibitors 46
5.5.1 NovoSeven RT (coagulation factor VIIa [recombinant]) 46

6 Opportunity and Unmet Need 48
6.1 Overview 48
6.2 Opportunities Analysis 49
6.2.1 Longer-Lasting Recombinant Factors to Reduce the Frequency of Prophylactic Injections 49
6.2.2 Lower-Cost Recombinant Replacement Therapies 50
6.2.3 Lower Risk of Inhibitor Formation in Previously Untreated Patients 51
6.2.4 More Convenient Drug Administration 51
6.2.5 Oral Formulation of Recombinant Replacement Therapies 52
6.3 Unmet Needs Gap Analysis 52
6.3.1 Long-Acting FVIII Replacement Therapies 52
6.3.2 Gene Therapy Treatments for Hemophilia A and B 53
7 Pipeline Assessment 54
7.1 Overview 54
7.2 Promising Drugs in Clinical Development - Hemophilia A 54
7.2.1 BAY 94-9027 (octocog alfa) 56
7.2.2 BAX-855 59
7.2.3 Novoeight (turoctocog alfa; NN7008) 63
7.2.4 N8-GP (NN7088) 66
8 Market Outlook 70
8.1 China 70
8.1.1 Forecast 70
8.1.2 Key Events 73
8.1.3 Drivers and Barriers 73
9 Appendix 75
9.1 Bibliography 75
9.2 Abbreviations 83

9.3 Methodology 86
9.4 Forecasting Methodology 86
9.4.1 Diagnosed Hemophilia Patients 87
9.4.2 Percent Drug-Treated Patients 87
9.4.3 Drugs Included in Each Therapeutic Class 88
9.4.4 Launch and Patent Expiry Dates 88
9.4.5 General Pricing Assumptions 89
9.4.6 Individual Drug Assumptions 89
9.4.7 Pricing of Pipeline Agents 92
9.5 Physicians and Specialists Included in this Study 93
9.6 About the Authors 95
9.6.1 Authors 95
9.6.2 Global Head of Healthcare 96
9.7 About GlobalData 97
9.8 Disclaimer 97

1.1 List of Tables

Table 1: Symptoms of Hemophilia A and B 18
Table 2: Most Prescribed Hemophilia A and B Drugs in the Global Markets, 2013 23
Table 3: Leading Recombinant Replacement Therapies for Hemophilia A and B and Patients with Inhibitors, 2013 29
Table 4: Leading Plasma-Based Replacement Therapies for Hemophilia A and B and Patients with Inhibitors, 2012 30
Table 5: Product Profile - Advate (octocog alfa; Antihemophilic Factor [Recombinant] Plasma/Albumin-Free) 32
Table 6: Advate SWOT Analysis, 2013 34
Table 7: Product Profile - Kogenate FS/Helixate FS (Antihemophilic Factor (Recombinant)) 36
Table 8: Kogenate FS/Helixate FS SWOT Analysis, 2013 38
Table 9: Product Profile - Recombinate (octocog alfa; Antihemophilic Factor [Recombinant] Plasma/Albumin-Free) 39

Table 10: Recombinate SWOT Analysis, 2013 40
Table 11: Product Profile - BeneFIX (nonacog alfa; coagulation factor IX [recombinant]) 41
Table 12: BeneFIX SWOT Analysis, 2013 42
Table 13: Product Profile - Rixubis (BAX-326) 44
Table 14: Rixubis SWOT Analysis, 2013 45
Table 15: Product Profile - NovoSeven RT (coagulation factor VIIa [recombinant]) 46
Table 16: NovoSeven RT SWOT Analysis, 2013 47
Table 17: Overall Unmet Needs - Current Level of Attainment 49
Table 18: Hemophilia A - Phase I/II Pipeline, 2013 54
Table 19: Hemophilia A - Phase III Pipeline, 2013 55
Table 20: Product Profile - BAY 94-9027 56
Table 21: BAY 94-9027 SWOT Analysis, 2013 59
Table 22: Product Profile - BAX-855 60
Table 23: BAX-855 SWOT Analysis, 2013 62
Table 24: Product Profile - Novoeight (turoctocog alfa; NN7008) 63
Table 25: Novoeight SWOT Analysis, 2013 66
Table 26: Product Profile - N8-GP (NN7088) 67
Table 27: N8-GP SWOT Analysis, 2013 69
Table 28: Sales Forecasts ($m) for Hemophilia A and B in China, 2012-2022 71
Table 29: Key Events Impacting Sales for Hemophilia A and B in China, 2013 73
Table 30: Chinese Hemophilia A and B Market - Drivers and Barriers, 2013 73
Table 31: Product Launch Dates 88
Table 32: Physicians Surveyed 93

1.2 List of Figures

Figure 1: Competitive Assessment of Late-Stage Pipeline Agents in Hemophilia A, 2012-2022 55
Figure 2: Sales for Hemophilia A and B in China by Drug Class, 2012-2022 72

To order this report: PharmaPoint: Hemophilia A and B - China Drug Forecast and Market Analysis to 2022
http://www.reportlinker.com/p01957666/PharmaPoint-Hemophilia-A-and-B---China-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
The IoTs will challenge the status quo of how IT and development organizations operate. Or will it? Certainly the fog layer of IoT requires special insights about data ontology, security and transactional integrity. But the developmental challenges are the same: People, Process and Platform. In his session at @ThingsExpo, Craig Sproule, CEO of Metavine, will demonstrate how to move beyond today's coding paradigm and share the must-have mindsets for removing complexity from the development proc...
SYS-CON Events announced today TechTarget has been named “Media Sponsor” of SYS-CON's 18th International Cloud Expo, which will take place on June 7–9, 2016, at the Javits Center in New York City, NY, and the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. TechTarget is the Web’s leading destination for serious technology buyers researching and making enterprise technology decisions. Its extensive global networ...
SYS-CON Events announced today that MangoApps will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. MangoApps provides modern company intranets and team collaboration software, allowing workers to stay connected and productive from anywhere in the world and from any device. For more information, please visit https://www.mangoapps.com/.
SYS-CON Events announced today that Commvault, a global leader in enterprise data protection and information management, has been named “Bronze Sponsor” of SYS-CON's 18th International Cloud Expo, which will take place on June 7–9, 2016, at the Javits Center in New York City, NY, and the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Commvault is a leading provider of data protection and information management...
The essence of data analysis involves setting up data pipelines that consist of several operations that are chained together – starting from data collection, data quality checks, data integration, data analysis and data visualization (including the setting up of interaction paths in that visualization). In our opinion, the challenges stem from the technology diversity at each stage of the data pipeline as well as the lack of process around the analysis.
A strange thing is happening along the way to the Internet of Things, namely far too many devices to work with and manage. It has become clear that we'll need much higher efficiency user experiences that can allow us to more easily and scalably work with the thousands of devices that will soon be in each of our lives. Enter the conversational interface revolution, combining bots we can literally talk with, gesture to, and even direct with our thoughts, with embedded artificial intelligence, wh...
Many banks and financial institutions are experimenting with containers in development environments, but when will they move into production? Containers are seen as the key to achieving the ultimate in information technology flexibility and agility. Containers work on both public and private clouds, and make it easy to build and deploy applications. The challenge for regulated industries is the cost and complexity of container security compliance. VM security compliance is already challenging, ...
SYS-CON Events announced today that Alert Logic, Inc., the leading provider of Security-as-a-Service solutions for the cloud, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Alert Logic, Inc., provides Security-as-a-Service for on-premises, cloud, and hybrid infrastructures, delivering deep security insight and continuous protection for customers at a lower cost than traditional security solutions. Ful...
In his session at 18th Cloud Expo, Bruce Swann, Senior Product Marketing Manager at Adobe, will discuss how the Adobe Marketing Cloud can help marketers embrace opportunities for personalized, relevant and real-time customer engagement across offline (direct mail, point of sale, call center) and digital (email, website, SMS, mobile apps, social networks, connected objects). Bruce Swann has more than 15 years of experience working with digital marketing disciplines like web analytics, social med...
Designing IoT applications is complex, but deploying them in a scalable fashion is even more complex. A scalable, API first IaaS cloud is a good start, but in order to understand the various components specific to deploying IoT applications, one needs to understand the architecture of these applications and figure out how to scale these components independently. In his session at @ThingsExpo, Nara Rajagopalan is CEO of Accelerite, will discuss the fundamental architecture of IoT applications, ...
Enterprise networks are complex. Moreover, they were designed and deployed to meet a specific set of business requirements at a specific point in time. But, the adoption of cloud services, new business applications and intensifying security policies, among other factors, require IT organizations to continuously deploy configuration changes. Therefore, enterprises are looking for better ways to automate the management of their networks while still leveraging existing capabilities, optimizing perf...
SYS-CON Events announced today that Tintri Inc., a leading producer of VM-aware storage (VAS) for virtualization and cloud environments, will exhibit at the 18th International CloudExpo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, New York, and the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
SYS-CON Events announced today that ContentMX, the marketing technology and services company with a singular mission to increase engagement and drive more conversations for enterprise, channel and SMB technology marketers, has been named “Sponsor & Exhibitor Lounge Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York City, New York. “CloudExpo is a great opportunity to start a conversation with new prospects, but what happens after the...
In the rush to compete in the digital age, a successful digital transformation is essential, but many organizations are setting themselves up for failure. There’s a common misconception that the process is just about technology, but it’s not. It’s about your business. It shouldn’t be treated as an isolated IT project; it should be driven by business needs with the committed involvement of a range of stakeholders.
SYS-CON Events announced today that EastBanc Technologies will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. EastBanc Technologies has been working at the frontier of technology since 1999. Today, the firm provides full-lifecycle software development delivering flexible technology solutions that seamlessly integrate with existing systems – whether on premise or cloud. EastBanc Technologies partners with p...